{"id":"NCT00799825","sponsor":"GlaxoSmithKline","briefTitle":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US","officialTitle":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01-01","primaryCompletion":"2012-08-02","completion":"2012-08-02","firstPosted":"2008-12-01","resultsPosted":"2013-09-20","lastUpdate":"2018-07-12"},"enrollment":346,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biological's HPV vaccine GSK580299 (Cervarixâ„¢)","otherNames":["CervarixTM"]}],"arms":[{"label":"Cervarix group","type":"EXPERIMENTAL"}],"summary":"This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).","primaryOutcome":{"measure":"Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)","timeFrame":"Throughout the study (up to Month 12)","effectByArm":[{"arm":"Cervarix Group","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":48,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":344},"commonTop":[]}}